Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides
about
Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolidesNovel antibacterial class.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.The evolution and role of macrolides in infectious diseases.Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E)Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.Drug Resistance Characteristics and Macrolide-Resistant Mechanisms of Streptococcus pneumoniae in Wenzhou City, China.Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study.Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.The mef(E)-carrying genetic element (mega) of Streptococcus pneumoniae: insertion sites and association with other genetic elements.Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates.Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.Tn2009, a Tn916-like element containing mef(E) in Streptococcus pneumoniae.In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271.Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs varyEfficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.
P2860
Q33856609-21AF3035-1DFA-41A0-8E57-06731518A0A5Q34076998-575D32BE-4205-4C32-B349-F3C4D343E6BEQ34107785-444DBAAF-8FD3-476C-97E1-0A18ACAA042EQ34123790-435007D7-E683-4AD1-ABD2-2E498F91E323Q34230515-C35A4FC0-66A3-4086-A918-24A9B3F9D4C6Q34281970-21E8D7E1-0DCF-4342-B21E-9A4C9928A7CCQ34749258-15EC1A3E-8B5A-4FE2-AF56-9CCE957856B2Q34768513-2647FB9A-3054-4A2E-8595-E3096D06752DQ34820774-A04E7866-1422-48B0-B992-01010E825F8EQ35013962-D9B35C59-2FB7-4481-A814-004607D2A6A1Q35690406-66EFB4E0-8814-4B6E-91BB-72A5DFA54CF3Q36081307-54D925E9-0351-4CF0-B904-E118A82036CCQ36170473-6B0D0BAA-8E6D-4435-BC91-BF4A01C8C9DBQ36670675-737737E4-4385-48FF-9D2F-5CA3965072D6Q37152559-9930131C-6CD5-4A9E-8CCD-10B86CA779F9Q37190854-002D8317-BB4D-4B70-845C-C60FDEA32915Q37274742-FEAD362D-CFC8-42D4-8628-08219C4307F9Q37525663-BADEAC0E-F638-4D70-992D-604FE0D9D4C9Q38665301-1B45E63B-FEC0-4956-A87A-7435B7660023Q39485994-EF1AA3BC-B205-40E0-87E1-B48CC8319F11Q39671236-5E1BCFC0-3E60-45F2-B02E-623E0D661752Q39730800-4C23918B-B4A9-4ABA-A979-640E187C44ECQ40165104-9801A5EE-D87D-49B7-B6EA-E60AA04F8E68Q40882823-01BFAEAC-5C45-4E24-8BF0-DBB6156019E7Q42111255-C5A982D0-0F91-484A-9B2A-3BB0E1D92AEAQ42112108-87BBA508-C3C7-4B05-AFD2-4C8558518DADQ42252396-FE990D00-F7A5-4302-ADD5-37CCB69C9C1CQ43151670-6104AAD6-E2C5-4F04-8821-8A359A2D3A42
P2860
Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@ast
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@en
type
label
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@ast
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@en
prefLabel
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@ast
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@en
P2093
P2860
P1476
Macrolide-resistant Streptococ ...... susceptibilities to ketolides
@en
P2093
A K Wierzbowski
G G Zhanel
P2860
P304
P356
10.1128/AAC.45.7.2147-2150.2001
P407
P577
2001-07-01T00:00:00Z